Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jessie P, Hong"'
Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges.
Autor:
Eung-Jun Im, Jessie P Hong, Yaowaluck Roshorm, Anne Bridgeman, Sven Létourneau, Peter Liljeström, Mary Jane Potash, David J Volsky, Andrew J McMichael, Tomáš Hanke
Publikováno v:
PLoS Pathogens, Vol 7, Iss 5, p e1002041 (2011)
Immunodominance in T cell responses to complex antigens like viruses is still incompletely understood. Some data indicate that the dominant responses to viruses are not necessarily the most protective, while other data imply that dominant responses a
Externí odkaz:
https://doaj.org/article/57b8c2a950d448ea9a709abb743a6a71
Autor:
David J. Volsky, Galina Bentsman, Tomáš Hanke, Manisha Saini, Eran Hadas, Leroy R. Sharer, Jennifer Kelschenbach, Jessie P. Hong, Mary Jane Potash, Wei Chao, Chao-Jiang Gu
Infection by some viruses induces immunity to reinfection, providing a means to identify protective epitopes. To investigate resistance to reinfection in an animal model of HIV disease and its control, we employed infection of mice with chimeric HIV,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4309c57b08d288977a2100d767f5f19f
https://ora.ox.ac.uk/objects/uuid:97ab058d-ab3a-4838-8e3b-f38699e98e42
https://ora.ox.ac.uk/objects/uuid:97ab058d-ab3a-4838-8e3b-f38699e98e42
Autor:
Andrew J. McMichael, Yaowaluck Roshorm, David J. Volsky, Jessie P. Hong, Naoki Kobayashi, Masafumi Takiguchi, Tomáš Hanke, Mary Jane Potash
Publikováno v:
European Journal of Immunology. 39:1831-1840
Novel candidate HIV-1 vaccines have been constructed, which are tailor-designed for HLA-B*5101+ patients infected with HIV-1 clade B. These vaccines employ novel immunogen HIVB-B*5101 derived from consensus HIV-1 clade B Gag p17 and p24 regions coupl
Autor:
Yaowaluck, Roshorm, Jessie P, Hong, Naoki, Kobayashi, Andrew J, McMichael, David J, Volsky, Mary Jane, Potash, Masafumi, Takiguchi, Tomás, Hanke
Publikováno v:
European journal of immunology. 39(7)
Novel candidate HIV-1 vaccines have been constructed, which are tailor-designed for HLA-B*5101(+) patients infected with HIV-1 clade B. These vaccines employ novel immunogen HIVB-B*5101 derived from consensus HIV-1 clade B Gag p17 and p24 regions cou